← Pharma and BioTech Daily
Pharma and BioTech Daily
Eli Lilly's $1.9B Abbisko Partnership Boosts Cancer R&D | Pharma and Biotech Daily
00:05:08
Loading summary
Transcript2 lines
- [00:00]
A
Biotech Daily is now open for sponsors and job of the week listings. If you want to reach biotech or pharma operators, scientists, founders and investors, you can book a single episode, a full week or promote an open role, all directly by visiting sponsor O with AI that's sponsor owith AI.
- [00:20]
B
Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we delve into a series of impactful developments shaping the future of medical innovation in patient care. The landscape of pharmaceutical and biotech industries is currently experiencing notable shifts driven by scientific advancements, regulatory updates and strategic collaborations. One of the more controversial events involves the retraction of a high profile study in Nature Medicine. This study initially suggested that the timing of PD1 inhibitor administration had significant impacts on survival rates for non small cell lung cancer patients. Early day administration was linked to improved outcomes compared to later in the day. However, after a four month investigation, concerns over methodological validity led to its retraction. This incident serves as a stark reminder of the necessity for rigorous peer review and transparency in clinical research, which are essential for influencing treatment protocols effectively. In industry news, Eli Lilly has entered into a major $1.9 billion partnership with Abisco Therapeutics to harness Abisco's drug discovery capabilities, particularly in Oncolog. This collaboration highlights an increasing trend where Western pharmaceutical companies team up with Asian biotech firms to accelerate drug development and tap into innovative therapeutic platforms. Eli Lilly is also recalibrating its strategy for launching its oral obesity treatment in Europe as it navigates the complexities introduced by the Most Favored Nation pricing agreement with the U.S. this underscores a broader challenge within the industry. Balancing pricing regulations with expanding access through digital health channels like Telehealth. ADC Therapeutics is taking steps to address safety concerns surrounding its antibody drug conjugate Zinlanta by reducing ITS workforce by 17%. This strategic realignment demonstrates the delicate balance companies must maintain between advancing promising therapies and ensuring patient safety through vigilant clinical oversight. On the regulatory front, Incyte's decision to drop its lawsuit against CMS over drug classification issues involving its JAK inhibitor Opazil Aura, highlights ongoing negotiations between pharmaceutical companies and regulatory bodies. These classifications have direct implications for market access and reimbursement strategies. Shifting focus to infrastructure advancel's move to establish its US Headquarters near Boston for radiopharmaceutical production underscores an emphasis on localizing drug manufacturing facilities to enhance supply chain resilience. This decision aligns with broader efforts to support domestic clinical trials for innovative therapies targeting prostate cancer. In terms of technological innovation, Novartis has invested $105 million upfront in Antares Therapeutics to target historically undruggable cancer proteins through small molecule development. This move reflects an industry wide push towards exploiting cutting edge technologies like AI driven drug discovery to meet unmet medical needs. In oncology. Precision medicine continues to gain traction, exemplified by Abbott's partnership with alspath to develop blood based diagnostic tests for Alzheimer's disease. Collaborations such as these are pivotal in enhancing early diagnosis and personalized treatment approaches for neurodegenerative disorders. Meanwhile, the industry's financial dynamics continue to evolve with significant fundraising activities. Sarafa Bio's public debut through a reverse merger with boundless bio raised $230 million, highlighting a growing trend of utilizing reverse mergers as a pathway to public markets. This financial boost comes alongside their licensing of a gene editing technology from China, underscoring the global nature of biotech collaborations in oncology, Eli Lilly's extended partnership with Abisco Therapeutics underscores the ongoing commitment to precision medicine, aiming to harness small molecule innovations targeting specific cancer pathways. Concurrently, the European Medicines Agency approved Astellas Padsiv combined with Merck and Cos Keytruda for muscle invasive bladder cancer treatment based on promising phase three results. Ophthalmology research is also seeing substantial investment with all in Biosciences, raising $330 million in series B funding aimed at developing therapies that challenge existing treatments like Vabismo for eye diseases. Such investments indicate strong confidence in novel therapies that could redefine standards in treating conditions like wet age related macular degeneration. In conclusion, these developments reflect a vibrant biotech and pharma landscape characterized by strategic partnerships, innovative financing mechanisms and regulatory milestones that collectively Dr. Forward scientific progress and enhance therapeutic options available worldwide. As these sectors continue to evolve, integrating cutting edge technologies like gene editing and precision oncology will be pivotal in shaping healthcare delivery's future trajectory while improving patient outcomes globally.